Clinical Trials Browser

Interventional × Recurrence × Imatinib Mesylate × Clear all

NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1 Completed

326 enrolled 1 FDA

MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00036738 2020-01-29

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Phase 2 Completed

28 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01172548 2017-05-31

INV555

Phase 2 Completed

GastrointestinalSarcoma

Recurrence, Gastrointestinal Stromal Tumors

NCT00840450 2012-11-19

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Phase 2 Terminated

14 enrolled 10 charts

Ovarian Neoplasms, Recurrence

NCT00243191 2012-03-29

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

Phase 2 Completed

18 enrolled 7 charts

Recurrence, Dermatofibrosarcoma